CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $174.59M, lower than 95% of all stocks globally
- PositionReturn on equity is -178.4%, lower than 95% of its Biotechnology peers (median -22.3%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
174.59MUSDvs all stocks (USD)
Revenue (TTM)
50.94MUSDvs all stocks (USD)
Profit Margin
-259.41%vs Biotechnology peers
Beta
0.9420xvs all stocks
52-Week Change
-33.53%vs all stocks
Market Capitalization
174.59MUSDvs all stocks (USD)
Enterprise Value
123.46MUSDvs all stocks (USD)
Forward P/E
-1.79xvs Biotechnology peers
Price to Sales (TTM)
3.43xvs Biotechnology peers
Price to Book (MRQ)
2.87xvs Biotechnology peers
Enterprise to Revenue
2.42xvs Biotechnology peers
Enterprise to EBITDA
-0.8210xvs Biotechnology peers
Gross Margin
70.35%vs Biotechnology peers
Profit Margin
-259.41%vs Biotechnology peers
Operating Margin
-225.98%vs Biotechnology peers
Return on Assets (TTM)
-30.52%vs Biotechnology peers
Return on Equity (TTM)
-178.39%vs Biotechnology peers
Revenue (TTM)
50.94MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.3860USDUpdated Sep 27, 2026Quarterly Revenue Growth
39.50%vs Biotechnology peers
Gross Profit (TTM)
35.12MUSDvs all stocks (USD)
EBITDA (TTM)
-150.39MUSDvs all stocks (USD)
Net Income (TTM)
-161.15MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
39.53%vs Biotechnology peers
Operating Cash Flow (TTM)
-186.03MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-160.15MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
42.17MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
13.81MUSDFY2025 · Dec 31, 2025Gross Profit
28.36MUSDFY2025 · Dec 31, 2025Operating Income
-181.13MUSDvs all stocks (USD)
Pre-tax Income
-183.12MUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
168.02MUSDFY2025 · Dec 31, 2025EBIT
-174.12MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-170.20MUSDFY2025 · Dec 31, 2025Research & Development
108.89MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
100.60MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
9.00MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
168.02MUSDFY2025 · Dec 31, 2025Operating Cash Flow
299.93MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
89.12MUSDFY2025 · Dec 31, 2025Income Tax Paid
36.00KUSDFY2025 · Dec 31, 2025Interest Paid
9.92MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
168.02MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
3.92MUSDFY2025 · Dec 31, 2025Stock-based Compensation
16.97MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-10.33MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
93.56MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-19.56MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
47.34MUSDFY2025 · Dec 31, 2025Net Acquisitions
457.81MUSDFY2025 · Dec 31, 2025Purchase of Investments
-103.84MUSDFY2025 · Dec 31, 2025Sale of Investments
21.46MUSDFY2025 · Dec 31, 2025Other Investing Activity
-342.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
375.09MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-280.84MUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.11MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-274.06MUSDFY2025 · Dec 31, 2025Shares Outstanding
154.47MSharesUpdated Sep 27, 2026Float Shares
135.60MSharesUpdated Sep 27, 2026Shares Short
22.85MSharesUpdated Sep 27, 2026Short Ratio
20.97daysvs all stocks
Short % of Shares Outstanding
15.24%vs all stocks
% Held by Insiders
19.12%vs all stocks
% Held by Institutions
37.45%vs all stocks
Total Cash (MRQ)
105.31MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.6820USDUpdated Sep 27, 2026Total Debt (MRQ)
54.18MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.8905xvs Biotechnology peers
Current Ratio (MRQ)
1.77xvs Biotechnology peers
Book Value per Share (MRQ)
0.3940USDUpdated Sep 27, 2026Total Assets
258.34MUSDvs all stocks (USD)
Total Current Assets
206.71MUSDFY2025 · Dec 31, 2025Total Liabilities
197.33MUSDFY2025 · Dec 31, 2025Total Non-current Assets
51.64MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
55.45MUSDFY2025 · Dec 31, 2025Total Current Liabilities
141.88MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
88.88MUSDFY2025 · Dec 31, 2025Other Short-term Investments
83.25MUSDFY2025 · Dec 31, 2025Accounts Receivable
17.82MUSDFY2025 · Dec 31, 2025Inventory
3.17MUSDFY2025 · Dec 31, 2025Accounts Payable
9.91MUSDFY2025 · Dec 31, 2025Short-term Debt
1.83MUSDFY2025 · Dec 31, 2025Other Current Liabilities
1.49MUSDFY2025 · Dec 31, 2025Long-term Debt
38.51MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
15.84MUSDFY2025 · Dec 31, 2025Common Stock (Book)
12.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.38BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
61.01MUSDvs all stocks (USD)
52-Week Low
1.09USDUpdated Sep 27, 202652-Week High
2.62USDUpdated Sep 27, 202652-Week Change
-33.53%vs all stocks
Beta
0.9420xvs all stocks
50-Day MA
1.35USDUpdated Sep 27, 2026200-Day MA
1.58USDUpdated Sep 27, 2026Avg 10-Day Volume
1.88MSharesUpdated Sep 27, 2026Avg 30-Day Volume
1.34MSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-1.16USDUpdated Sep 27, 2026Other Income / Expense
7.01MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Diagnostic
Elevated ROE With High Debt-to-Equity and Equity Multiplier
Return on equity reads high on a balance sheet carrying a lot of debt against that equity.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -178.4%, lower than 95% of its Biotechnology peers (median -22.3%)Significant
Return on equity: -1.78Industry median: -0.22Industry P5: -1.57Peers compared: 260
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.70Profit Margin: -2.59
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $174.59M, lower than 95% of all stocks globallySignificant
Market cap (USD): 174,586,091Global P5: 275,556,405.438
Companies that share the same coordination system — how they create, deliver, or capture value.
ADC Therapeutics S.A.
Tier 1ProductionApproval-Gated PipelineRule
NervGen Pharma Corp.
Tier 1ProductionApproval-Gated PipelineRule
Alx Oncology Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Asterasys Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Organogenesis Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
MediWound Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Cabio Biotech Wuhan Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Intocell Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Hans Biomed Corp.
Tier 1ProductionApproval-Gated PipelineRule
Alector Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
1 interpretationElevated ROE With High Debt-to-Equity and Equity Multiplier
Shenzhen Liantronics Co., Ltd.
1 interpretationElevated ROE With High Debt-to-Equity and Equity Multiplier
GPS Participações e Empreendimentos S.A.
1 interpretationElevated ROE With High Debt-to-Equity and Equity Multiplier